trial

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

NCTId NCT01012167
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 86 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2014-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
86 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-02
Primary completion
2014-07
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
OxytocinGalantamine

Sponsors

University of Maryland, Baltimore CountyLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
William R. McFarlane, M.D.Principal Investigator

Sites

6 total
Baltimore, United StatesBaltimore, United StatesBaltimore, United StatesBaltimore, United StatesCatonsville, United StatesDundalk, United States

Linked catalysts

1
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms an — primary completion2014-07

Facts & assertions

4 sourced
Enrollment
86
Phase
PHASE2
Primary Completion Date
2014-07
Status
COMPLETED
relationships
The graph out of here
drug
Oxytocin
drug
Galantamine
drug
lead_sponsor
University of Maryland, Baltimore County
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
William R. McFarlane, M.D.
person